{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:59:07Z","timestamp":1779890347118,"version":"3.53.1"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ejphar.2021.174272","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T07:25:17Z","timestamp":1623914717000},"page":"174272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"907","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3177-2129","authenticated-orcid":false,"given":"Evangelia S.","family":"Makri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonis","family":"Goulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2021.174272_bib1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/hepr.13304","article-title":"Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus","volume":"49","author":"Akuta","year":"2019","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2021.174272_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2021.174272_bib3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.174272_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block","volume":"18","author":"Athyros","year":"2020","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174272_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s13340-016-0302-y","article-title":"The effects of ipragliflozin on the liver-to-spleen attenuation ratio as assessed by computed tomography and on alanine transaminase levels in Japanese patients with type 2 diabetes mellitus","volume":"8","author":"Bando","year":"2017","journal-title":"Diabetol Int"},{"key":"10.1016\/j.ejphar.2021.174272_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.174272_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2021.174272_bib9","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2021.174272_bib10","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s10620-017-4470-9","article-title":"Activation of insulin-PI3K\/Akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis","volume":"62","author":"Cai","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejphar.2021.174272_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","article-title":"Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial","volume":"382","author":"Cefalu","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2021.174272_bib12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2021.174272_bib13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2021.174272_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejphar.2021.174272_bib15","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: a meta-analysis of randomized clinical trials","author":"Coelho","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.ejphar.2021.174272_bib16","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2021.174272_bib17","doi-asserted-by":"crossref","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","article-title":"Metabolic liver disease in diabetes - from mechanisms to clinical trials","volume":"111s","author":"Dewidar","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib18","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"Easl-Easd-Easo","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174272_bib19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2019.01.042","article-title":"Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease","volume":"156","author":"Eddowes","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2021.174272_bib20","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2021.174272_bib21","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2021.174272_bib22","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174272_bib23","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2021.174272_bib24","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ejphar.2021.174272_bib25","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejphar.2021.174272_bib26","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.174272_bib27","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2021.174272_bib28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/dom.14319","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2021.174272_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2015.02.009","article-title":"Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats","volume":"754","author":"Hayashizaki-Someya","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174272_bib30","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174272_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146337","article-title":"The selective SGLT2 inhibitor ipragliflozin has a therapeutic effect on nonalcoholic steatohepatitis in mice","volume":"11","author":"Honda","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2021.174272_bib32","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2021.174272_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13098-016-0169-x","article-title":"Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes","volume":"8","author":"Jojima","year":"2016","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.ejphar.2021.174272_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejphar.2018.03.043","article-title":"Canagliflozin protects against non-alcoholic steatohepatitis in type-2 diabetic rats through zinc alpha-2 glycoprotein up-regulation","volume":"828","author":"Kabil","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2021.174272_bib35","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2021.174272_bib36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/dom.13577","article-title":"Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk","volume":"21","author":"Kim","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2021.174272_bib37","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1002\/jcb.28141","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and \u03b1-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes","volume":"120","author":"Kim","year":"2018","journal-title":"J. Cell. Biochem."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2021.174272_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/ajt.14559","article-title":"OPTN\/SRTR 2016 annual data report: liver","volume":"18","author":"Kim","year":"2018","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.ejphar.2021.174272_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.ejphar.2021.174272_bib40","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2021.174272_bib41","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejphar.2021.174272_bib42","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","article-title":"Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease","volume":"146","author":"Lambert","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2021.174272_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/1479164120975256","article-title":"Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME(\u00ae)","volume":"17","author":"Langslet","year":"2020","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.ejphar.2021.174272_bib44","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1479164114563304","article-title":"Development of sotagliflozin, a dual sodium-dependent glucose transporter 1\/2 inhibitor","volume":"12","author":"Lapuerta","year":"2015","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"10.1016\/j.ejphar.2021.174272_bib45","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2021.174272_bib46","article-title":"Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models","volume":"7","author":"Liang","year":"2012","journal-title":"PloS One"},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2021.174272_bib48","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/j.dsx.2016.12.033","article-title":"Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: a systematic review and meta-analysis","volume":"11","author":"Mahfood Haddad","year":"2017","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.ejphar.2021.174272_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.arcmed.2020.11.010","article-title":"Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease","volume":"52","author":"Makri","year":"2021","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.ejphar.2021.174272_bib50","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/metabo11010022","article-title":"Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.ejphar.2021.174272_bib51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib52","doi-asserted-by":"crossref","first-page":"107492","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.ejphar.2021.174272_bib53","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1080\/14656566.2016.1225727","article-title":"Emerging and future therapies for nonalcoholic steatohepatitis in adults","volume":"17","author":"Mintziori","year":"2016","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2021.174272_bib54","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.2337\/dc15-0642","article-title":"Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside","volume":"38","author":"Mudaliar","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2021.174272_bib55","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE((-\/-)) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2021.174272_bib56","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2021.174272_bib57","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ejphar.2021.174272_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/MCG.0000000000000400","article-title":"Insulin resistance is associated with significant liver fibrosis in chronic hepatitis C patients: a systemic review and meta-analysis","volume":"50","author":"Patel","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.ejphar.2021.174272_bib59","doi-asserted-by":"crossref","first-page":"110539","DOI":"10.1016\/j.mce.2019.110539","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2021.174272_bib60","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejphar.2021.174272_bib61","doi-asserted-by":"crossref","first-page":"154203","DOI":"10.1016\/j.metabol.2020.154203","article-title":"Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis","volume":"111s","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib62","doi-asserted-by":"crossref","first-page":"92","DOI":"10.23736\/S0391-1977.16.02563-3","article-title":"Adipose tissue, obesity and non-alcoholic fatty liver disease","volume":"42","author":"Polyzos","year":"2017","journal-title":"Minerva Endocrinol."},{"key":"10.1016\/j.ejphar.2021.174272_bib63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib64","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/156652409787847191","article-title":"Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines","volume":"9","author":"Polyzos","year":"2009","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/j.ejphar.2021.174272_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.metabol.2013.10.010","article-title":"Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease","volume":"63","author":"Polyzos","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib66","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.metabol.2015.12.009","article-title":"Nonalcoholic fatty future disease","volume":"65","author":"Polyzos","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib67","doi-asserted-by":"crossref","first-page":"154318","DOI":"10.1016\/j.metabol.2020.154318","article-title":"Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)","volume":"111s","author":"Polyzos","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib68","doi-asserted-by":"crossref","first-page":"E117","DOI":"10.1152\/ajpendo.00439.2012","article-title":"Improved glycemic control in mice lacking Sglt1 and Sglt2","volume":"304","author":"Powell","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2021.174272_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13098-015-0102-8","article-title":"Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus","volume":"7","author":"Qiang","year":"2015","journal-title":"Diabetol. Metab. Syndrome"},{"key":"10.1016\/j.ejphar.2021.174272_bib71","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2020.10.064","article-title":"Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials","volume":"232","author":"Salah","year":"2021","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ejphar.2021.174272_bib72","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2021.174272_bib73","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejphar.2021.174272_bib74","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-021-01014-0","article-title":"Efficacy and safety of luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, exploratory trial","volume":"12","author":"Seino","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejphar.2021.174272_bib75","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2021.174272_bib76","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejphar.2021.174272_bib77","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2152\/jmi.67.280","article-title":"Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus","volume":"67","author":"Shinozaki","year":"2020","journal-title":"J. Med. Invest."},{"key":"10.1016\/j.ejphar.2021.174272_bib79","article-title":"SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model","volume":"7","author":"Tahara","year":"2019","journal-title":"Phys. Rep."},{"key":"10.1016\/j.ejphar.2021.174272_bib80","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejphar.2021.174272_bib81","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174272_bib82","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","article-title":"Pharmacotherapy of type 2 diabetes: an update","volume":"78","author":"Upadhyay","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.ejphar.2021.174272_bib84","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2021.174272_bib85","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.117.028268","article-title":"Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease","volume":"137","author":"Wanner","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2021.174272_bib86","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ejphar.2021.174272_bib87","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s13300-020-00816-y","article-title":"Drug therapy in obesity: a review of current and emerging treatments","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejphar.2021.174272_bib88","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s13300-019-00747-3","article-title":"Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.ejphar.2021.174272_bib89","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2021.174272_bib90","doi-asserted-by":"crossref","first-page":"33386","DOI":"10.1038\/srep33386","article-title":"Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis","volume":"6","author":"Wu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2021.174272_bib91","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.ejphar.2021.174272_bib92","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejphar.2021.174272_bib93","doi-asserted-by":"crossref","first-page":"9116","DOI":"10.1073\/pnas.161284298","article-title":"A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver","volume":"98","author":"Yamashita","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejphar.2021.174272_bib94","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/17474124.2021.1860019","article-title":"A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD","volume":"15","author":"Yilmaz","year":"2021","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174272_bib95","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.ejphar.2021.174272_bib96","doi-asserted-by":"crossref","first-page":"111738","DOI":"10.1016\/j.biopha.2021.111738","article-title":"The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model","volume":"140","author":"Yoshioka","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2021.174272_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2021.174272_bib98","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2021.174272_bib99","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921004258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299921004258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:51:58Z","timestamp":1757976718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299921004258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":95,"alternative-id":["S0014299921004258"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174272","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2021.174272","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"174272"}}